title: Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy.
abstract: The kidney has numerous complex interactions with the heart, including shared risk factors (e.g., hypertension, dyslipidemia, etc.) and mutual amplification of morbidity and mortality. Both cardiovascular diseases and chronic kidney disease (CKD) may cause various alterations in cardiovascular system, metabolic homeostasis and autonomic nervous system that may facilitate the occurrence of cardiac arrhythmias. Also, pre-existent or incident cardiac arrhythmias such as atrial fibrillation (AF) may accelerate the progression of CKD. Patients with CKD may experience various cardiac rhythm disturbances including sudden cardiac death. Contemporary management of cardiac arrhythmias includes the use of antiarrhythmic drugs (AADs), catheter ablation and cardiac implantable electronic devices (CIEDs). Importantly, AADs are not used only as the principal treatment strategy, but also as an adjunct therapy in combination with CIEDs, to facilitate their effects or to minimize inappropriate device activation in selected patients. Along with their principal antiarrhythmic effect, AADs may also induce cardiac arrhythmias and the risk for such proarrhythmic effect(s) is particularly increased in patients with reduced left ventricular systolic function or in the setting of electrolyte imbalance. Moreover, CKD itself can induce profound alterations in the pharmacokinetics and pharmacodynamics of many drugs including AADs, thus facilitating the drug accumulation and increased exposure. Hence, the use of AADs in patients with CKD may be challenging. In this review article, we provide an overview of the characteristics of arrhythmogenesis in patients with CKD with special emphasis on the complexity of pharmacokinetics and risk for proarrhythmias when using AADs in patients with cardiac arrhythmias and CKD.
authors.affiliation: Cardiology Clinic, Clinical Centre of Serbia, School of Medicine, University of Belgrade, Serbia, Visegradska 26, 11000 Belgrade, Serbia. tanjapotpara@gmail.com.
authors.forename: Tatjana S
authors.initials: TS
authors.lastname: Potpara
authors.forename: Vera
authors.initials: V
authors.lastname: Jokic
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Dagres
authors.forename: Francisco
authors.initials: F
authors.lastname: Marin
authors.forename: Milica S
authors.initials: MS
authors.lastname: Prostran
authors.forename: Carina
authors.initials: C
authors.lastname: Blomstrom-Lundqvist
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000188:drug therapy*; D050197:Atherosclerosis / Q000150:complications / Q000188:drug therapy; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004573:Electrolytes / Q000378:metabolism; D005919:Glomerular Filtration Rate; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D004573:Electrolytes